001     168440
005     20240229133609.0
024 7 _ |a 10.1080/19490976.2021.1903825
|2 doi
024 7 _ |a pmid:33874856
|2 pmid
024 7 _ |a 1949-0976
|2 ISSN
024 7 _ |a 1949-0984
|2 ISSN
024 7 _ |a altmetric:104338069
|2 altmetric
037 _ _ |a DKFZ-2021-00914
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Butt, Julia Anna
|0 P:(DE-He78)31d7c3e829be03400641f80b821ef728
|b 0
|e First author
|u dkfz
245 _ _ |a Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort.
260 _ _ |a Austin, Tex.
|c 2021
|b Landes Bioscience
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1663758585_25469
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:F022# /Jan-Dec 2021;13(1):1-14 / 1903825
520 _ _ |a Experimental evidence has implicated genotoxic Escherichia coli (E. coli) and enterotoxigenic Bacteroides fragilis (ETBF) in the development of colorectal cancer (CRC). However, evidence from epidemiological studies is sparse. We therefore assessed the association of serological markers of E. coli and ETBF exposure with odds of developing CRC in the European Prospective Investigation into Nutrition and Cancer (EPIC) study.Serum samples of incident CRC cases and matched controls (n = 442 pairs) were analyzed for immunoglobulin (Ig) A and G antibody responses to seven E. coli proteins and two isoforms of the ETBF toxin via multiplex serology. Multivariable-adjusted conditional logistic regression analyses were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of sero-positivity to E. coli and ETBF with CRC.The IgA-positivity of any of the tested E. coli antigens was associated with higher odds of developing CRC (OR: 1.42; 95% CI: 1.05-1.91). Dual-positivity for both IgA and IgG to E. coli and ETBF was associated with >1.7-fold higher odds of developing CRC, with a significant association only for IgG (OR: 1.75; 95% CI: 1.04, 2.94). This association was more pronounced when restricted to the proximal colon cancers (OR: 2.62; 95% CI: 1.09, 6.29) compared to those of the distal colon (OR: 1.24; 95% CI: 0.51, 3.00) (pheterogeneity = 0.095). Sero-positivity to E. coli and ETBF was associated with CRC development, suggesting that co-infection of these bacterial species may contribute to colorectal carcinogenesis. These findings warrant further exploration in larger prospective studies and within different population groups.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Colorectal cancer
|2 Other
650 _ 7 |a Escherichia coli
|2 Other
650 _ 7 |a bacteroides fragilis
|2 Other
650 _ 7 |a prospective
|2 Other
650 _ 7 |a serology
|2 Other
700 1 _ |a Jenab, Mazda
|0 0000-0002-0573-1852
|b 1
700 1 _ |a Werner, Jill
|b 2
700 1 _ |a Fedirko, Veronika
|b 3
700 1 _ |a Weiderpass, Elisabete
|b 4
700 1 _ |a Dahm, Christina C
|b 5
700 1 _ |a Tjønneland, Anne
|b 6
700 1 _ |a Olsen, Anja
|b 7
700 1 _ |a Boutron-Ruault, Marie-Christine
|b 8
700 1 _ |a Rothwell, Joseph A
|b 9
700 1 _ |a Severi, Gianluca
|0 0000-0001-7157-419X
|b 10
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 11
|u dkfz
700 1 _ |a Turzanski-Fortner, Renée
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 12
|u dkfz
700 1 _ |a Aleksandrova, Krasimira
|b 13
700 1 _ |a Schulze, Matthias
|b 14
700 1 _ |a Palli, Domenico
|b 15
700 1 _ |a Pala, Valeria
|b 16
700 1 _ |a Panico, Salvatore
|b 17
700 1 _ |a Tumino, Rosario
|b 18
700 1 _ |a Sacerdote, Carlotta
|b 19
700 1 _ |a Bueno-de-Mesquita, Bas
|b 20
700 1 _ |a Van Gils, Carla H
|0 0000-0003-0817-7567
|b 21
700 1 _ |a Gram, Inger Torhild
|b 22
700 1 _ |a Lukic, Marko
|b 23
700 1 _ |a Sala, Núria
|b 24
700 1 _ |a Sánchez Pérez, María José
|b 25
700 1 _ |a Ardanaz, Eva
|b 26
700 1 _ |a Chirlaque, María-Dolores
|b 27
700 1 _ |a Palmquist, Richard
|b 28
700 1 _ |a Löwenmark, Thyra
|b 29
700 1 _ |a Travis, Ruth C
|b 30
700 1 _ |a Heath, Alicia
|b 31
700 1 _ |a Cross, Amanda J
|b 32
700 1 _ |a Freisling, Heinz
|b 33
700 1 _ |a Zouiouich, Semi
|b 34
700 1 _ |a Aglago, Elom
|b 35
700 1 _ |a Waterboer, Tim
|0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
|b 36
|u dkfz
700 1 _ |a Hughes, David J
|0 0000-0003-1668-8770
|b 37
773 _ _ |a 10.1080/19490976.2021.1903825
|g Vol. 13, no. 1, p. 1 - 14
|0 PERI:(DE-600)2575755-6
|n 1
|p 1903825
|t Gut microbes
|v 13
|y 2021
|x 1949-0984
909 C O |p VDB
|o oai:inrepo02.dkfz.de:168440
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)31d7c3e829be03400641f80b821ef728
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 36
|6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-316
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Infections and cancer
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GUT MICROBES : 2019
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-30
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b GUT MICROBES : 2019
|d 2021-01-30
920 1 _ |0 I:(DE-He78)F022-20160331
|k F022
|l Infektionen und Krebs-Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)F020-20160331
|k F020
|l Infektionen und Krebs-Epidemiologie
|x 1
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F022-20160331
980 _ _ |a I:(DE-He78)F020-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21